These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 32163676)

  • 21. Flare on Serial Prostate-Specific Membrane Antigen-Targeted 18F-DCFPyL PET/CT Examinations in Castration-Resistant Prostate Cancer: First Observations.
    Zukotynski KA; Valliant J; Bénard F; Rowe SP; Kim CK; Pomper MG; Cho SY
    Clin Nucl Med; 2018 Mar; 43(3):213-216. PubMed ID: 29356735
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Repeated PSMA-targeting radioligand therapy of metastatic prostate cancer with
    Afshar-Oromieh A; Haberkorn U; Zechmann C; Armor T; Mier W; Spohn F; Debus N; Holland-Letz T; Babich J; Kratochwil C
    Eur J Nucl Med Mol Imaging; 2017 Jun; 44(6):950-959. PubMed ID: 28280855
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Restaging With Prostate-Specific Membrane Antigen Imaging in Metastatic Castration-Resistant Prostate Cancer: When Seeing More Is Detrimental to Care.
    Madan RA; Yu EY; Posadas EM; Lee RJ; Karzai F; Choyke PL
    J Clin Oncol; 2024 Jul; 42(19):2242-2244. PubMed ID: 38489582
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Favorable Response of 225 Ac-PSMA in the Treatment of Castration-Resistant Prostate Cancer With High Bone Metastasis Burden.
    Wang Y; Hua Q; Zhang Y; Wang W; Chen Y
    Clin Nucl Med; 2024 Jul; 49(7):674-676. PubMed ID: 38598741
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Global experience with PSMA-based alpha therapy in prostate cancer.
    Sathekge MM; Bruchertseifer F; Vorster M; Morgenstern A; Lawal IO
    Eur J Nucl Med Mol Imaging; 2021 Dec; 49(1):30-46. PubMed ID: 34173838
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reversible epigenetic alterations mediate PSMA expression heterogeneity in advanced metastatic prostate cancer.
    Sayar E; Patel RA; Coleman IM; Roudier MP; Zhang A; Mustafi P; Low JY; Hanratty B; Ang LS; Bhatia V; Adil M; Bakbak H; Quigley DA; Schweizer MT; Hawley JE; Kollath L; True LD; Feng FY; Bander NH; Corey E; Lee JK; Morrissey C; Gulati R; Nelson PS; Haffner MC
    JCI Insight; 2023 Apr; 8(7):. PubMed ID: 36821396
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Free TcO 4- in 99m Tc-PSMA Scan : A Case Report and Review of an Old Pitfall in the New Era of Modern Imaging.
    Sahafi P; Aryana K; Moghadam SZ; Sadri K; Askari E
    Clin Nucl Med; 2024 Jul; 49(7):e327-e328. PubMed ID: 38687008
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Prospective Trial of
    Wang B; Liu C; Wei Y; Meng J; Zhang Y; Gan H; Xu X; Wan F; Pan J; Ma X; Hu S; Freedland SJ; Song S; Ye D; Zhu Y
    Clin Cancer Res; 2020 Sep; 26(17):4551-4558. PubMed ID: 32527944
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cytoreductive radiotherapy combined with abiraterone in metastatic castration-resistance prostate cancer: a single center experience.
    Liu Y; Long W; Zhang Z; Mai L; Huang S; Liu B; Cao W; Wu J; Zhou F; Li Y; He L
    Radiat Oncol; 2021 Jan; 16(1):5. PubMed ID: 33407637
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MiR-205-driven downregulation of cholesterol biosynthesis through SQLE-inhibition identifies therapeutic vulnerability in aggressive prostate cancer.
    Kalogirou C; Linxweiler J; Schmucker P; Snaebjornsson MT; Schmitz W; Wach S; Krebs M; Hartmann E; Puhr M; Müller A; Spahn M; Seitz AK; Frank T; Marouf H; Büchel G; Eckstein M; Kübler H; Eilers M; Saar M; Junker K; Röhrig F; Kneitz B; Rosenfeldt MT; Schulze A
    Nat Commun; 2021 Aug; 12(1):5066. PubMed ID: 34417456
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ocular toxicity of bortezomib therapy.
    Arias-Peso B; Bakkali El Bakkali M; Tello Fernández A; Rodriguez-Marco NA
    J Fr Ophtalmol; 2021 Sep; 44(7):e429-e430. PubMed ID: 33832755
    [No Abstract]   [Full Text] [Related]  

  • 32. A case of segmental hepatic necrosis complicating oxaliplatin and capecitabine chemotherapy A case report and review of the literature.
    Di Sibio A; Varrassi M; Venditti O; Di Cesare E; Romano L; Giuliani A; De Donato MC; Carlei F; Parisi A; Schietroma M; Latessa M; Monti R; Ficorella C
    Ann Ital Chir; 2020 Sep; 9():. PubMed ID: 33021243
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hyperammonemic encephalopathy during XELOX regimen. Is it capecitabine or oxaliplatin responsible?
    Di Federico A; Nuvola G; Sisi M; Lenzi B; Nobili E; Campana D
    Anticancer Drugs; 2020 Nov; 31(10):1103-1105. PubMed ID: 32826413
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase 1 dose escalation trial of TAS-102 (trifluridine/tipiracil) and temozolomide in the treatment of advanced neuroendocrine tumors.
    Uboha NV; Lubner SJ; LoConte NK; Mulkerin DL; Eickhoff JC; Deming DA
    Invest New Drugs; 2020 Oct; 38(5):1520-1525. PubMed ID: 32253554
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of adjuvant chemotherapy on outcomes in appendiceal cancer.
    Kolla BC; Petersen A; Chengappa M; Gummadi T; Ganesan C; Gaertner WB; Blaes A
    Cancer Med; 2020 May; 9(10):3400-3406. PubMed ID: 32189461
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A double-blind, randomized, multicenter phase 3 study of palonosetron vs granisetron combined with dexamethasone and fosaprepitant to prevent chemotherapy-induced nausea and vomiting in patients with breast cancer receiving anthracycline and cyclophosphamide.
    Matsumoto K; Takahashi M; Sato K; Osaki A; Takano T; Naito Y; Matsuura K; Aogi K; Fujiwara K; Tamura K; Baba M; Tokunaga S; Hirano G; Imoto S; Miyazaki C; Yanagihara K; Imamura CK; Chiba Y; Saeki T
    Cancer Med; 2020 May; 9(10):3319-3327. PubMed ID: 32168551
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Crizotinib vs platinum-based chemotherapy as first-line treatment for advanced non-small cell lung cancer with different ROS1 fusion variants.
    Xu H; Zhang Q; Liang L; Li J; Liu Z; Li W; Yang L; Yang G; Xu F; Ying J; Zhang S; Wang Y
    Cancer Med; 2020 May; 9(10):3328-3336. PubMed ID: 32168429
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A patient-derived xenograft and a cell line derived from it form a useful preclinical model for small bowel adenocarcinoma.
    Yamano T; Kubo S; Tomita N
    Cancer Med; 2020 May; 9(10):3337-3343. PubMed ID: 32168428
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Current status and future perspective of radiopharmaceuticals in China.
    Hu J; Li H; Sui Y; Du J
    Eur J Nucl Med Mol Imaging; 2022 Jul; 49(8):2514-2530. PubMed ID: 34767047
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preliminary results of targeted prostate-specific membrane antigen imaging in evaluating the efficacy of a novel hormone agent in metastatic castration-resistant prostate cancer.
    Liu C; Zhu Y; Su H; Xu X; Zhang Y; Song S; Wang B; Ye D; Hu S
    Cancer Med; 2020 May; 9(10):3278-3286. PubMed ID: 32163676
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.